ArticleJournal of clinical medicine2021
Antihypertensive Drugs and the Risk of Cancer: A Nationwide Cohort Study.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Association between antihypertensive medication use and kidney cancer risk: a meta-analysis accounting for hypertension.BMC cancer · 2025Pooled it
- Antihypertensive Therapy and Survival Outcomes in Patients with Renal Cell Carcinoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Review
- Association between antihypertensive drugs and cancer risk: evidence from a population-based study in the Abruzzo region, Southern Italy.BMC cancer · 2025Article
- Diversified, endothelial cell-dependent cancer cell response to hypertensive serum modified by antihypertensive drugs.Scientific reports · 2025Article
- Serum from Hypertensive Patients Induces Cancer-Supporting Phenotype of Vascular Endothelium In Vitro.Biomolecules · 2024Article
- Cholesterol and Immune Microenvironment: Path Towards Tumorigenesis.Current nutrition reports · 2024Review
- Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- Associations between cardiovascular diseases and cancer mortality: insights from a retrospective cohort analysis of NHANES data.BMC public health · 2024Article
- The Risk of Colorectal Polyps after Weight Loss Therapy Versus Obesity: A Propensity-Matched Nationwide Cohort Study.Cancers · 2023Article
- Renin-angiotensin system inhibitors improve the survival of cholangiocarcinoma: a propensity score-matched cohort study.BMC cancer · 2023Article
- Review
- Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai.BMC cancer · 2023Article
- The impact of surgical weight loss procedures on the risk of metachronous colorectal neoplasia: the differential effect of surgery type, sex, and anatomic location.Journal of the National Cancer Institute. Monographs · 2023Article
- The risk of second primary malignancies in colorectal cancer patients using calcium channel blockers.Scientific reports · 2023Article
- Antihypertensive medications and risk of colorectal cancer in British Columbia.Frontiers in pharmacology · 2023Article
- Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population-Based Cohort Study.Journal of the American Heart Association · 2022Article
- A reverse translational pharmacological approach to understand the underlying mechanisms of the reported association between hydrochlorothiazide and non-melanoma skin cancer.Journal of hypertension · 2022Article
- Colorectal Cancer Risk Is Impacted by Sex and Type of Surgery After Bariatric Surgery.Obesity surgery · 2022Article
- Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome.Obesity (Silver Spring, Md.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 17 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to assess the association between common antihypertensive drugs and the risk of incident cancer in treated hypertensive patients. Using the Korean National Health Insurance Service database, the risk of cancer incidence was analyzed in patients with hypertension who were initially free of cancer and used the following antihypertensive drug classes: Angiotensin-converting enzyme inhibitors (ACEIs); angiotensin receptor blockers (ARBs); beta blockers (BBs); calcium channel blockers (CCBs); and diuretics. During a median follow-up of 8.6 years, there were 4513 (6.4%) overall cancer incidences from an initial 70,549 individuals taking antihypertensive drugs. ARB use was associated with a decreased risk for overall cancer in a crude model (hazard ratio (HR): 0.744, 95% confidence interval (CI): 0.696-0.794) and a fully adjusted model (HR: 0.833, 95% CI: 0.775-0.896) compared with individuals not taking ARBs. Other antihypertensive drugs, including ACEIs, CCBs, BBs, and diuretics, did not show significant associations with incident cancer overall. The long-term use of ARBs was significantly associated with a reduced risk of incident cancer over time. The users of common antihypertensive medications were not associated with an increased risk of cancer overall compared to users of other classes of antihypertensive drugs. ARB use was independently associated with a decreased risk of cancer overall compared to other antihypertensive drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.